Hostname: page-component-7479d7b7d-pfhbr Total loading time: 0 Render date: 2024-07-11T13:25:08.087Z Has data issue: false hasContentIssue false
  • English
  • Français

Bupropion in the treatment of adjustment disorder

Published online by Cambridge University Press:  24 June 2014

Rahul Sarkar  and
Stephanie Krüger
Rahul Sarkar*
Affiliation:
Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz, Berlin
Stephanie Krüger
Affiliation:
Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz, Berlin
*
Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, D-10117 Berlin, Germany Tel: (+49) 030 450617050; Fax: (+49) 030 450517922; E-mail: rahul.sarkar@charite.de
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Comment & Critique
Information
Acta Neuropsychiatrica , Volume 20 , Issue 5 , October 2008 , pp. 282 - 283
Copyright
Copyright © 2008 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 4th edn, text edition. Washington: American Psychiatric Association, 2000. Google ScholarPubMed
Mulrow, CD, Williams, JW, Trivedi, Met al. Treatment of depression: newer pharmacotherapies. Evid Rep Technol Assess (Summ) 1999;7:1–4. Google Scholar
Asher, JA, Cole, JO, Colin, JNet al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395–401. Google Scholar
Papakostas, GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 2006;16:391–402. CrossRefGoogle Scholar
San, L, Arranz, B. Mirtazapine: only for depression? Acta Neuropsychiatr 2006;18:130–143. CrossRefGoogle Scholar
ÁLamo, C, López-Muñoz, F, Rubio, G, García-García, P, Pardo, A. Combined treatment with reboxetine in depressed patients with no response to venlafaxine: a 6-week follow-up study. Acta Neuropsychiatr 2007;19:291–296. CrossRefGoogle ScholarPubMed